Shanghai Junshi Biosciences' sNDA for Toripalimab and Bevacizumab Combo for Advanced Liver Cancer Accepted by NMPA

  Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializati...

July 19, 2024 | Friday | News
Merck Invests €6.6 Million to Expand Cell Culture Media Production at Nantong Site

€ 6.6 million investment at Nantong site expands production capabilities for cell culture media  Supports local biopharma manufact...

July 16, 2024 | Tuesday | News
China's NMPA Approves First and Only Subcutaneous FcRn Blocker for gMG Patients

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigim...

July 16, 2024 | Tuesday | News
AusperBio Therapeutics Secures $37 Million Series A Financing

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to ...

July 15, 2024 | Monday | News
AHB-137 Receives Breakthrough Therapy Designation from NMPA, Paving the Way for Faster Access to Chronic Hepatitis B Treatment

AHB-137 gains Breakthrough Therapy Designation (BTD) from the NMPA based on Phase 1/Phase2a clinical trial data demonstrating safety and efficacy. BTD...

July 11, 2024 | Thursday | News
HUTCHMED's New aDrug Application for Tazemetostat in Relapsed or Refractory Follicular Lymphoma Granted Priority Review by China NMPA

HUTCHMED (China) Limited (“HUTCHMED”)  announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of...

July 04, 2024 | Thursday | News
Junshi Biosciences' Toripalimab Approved in China for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of nov...

June 18, 2024 | Tuesday | News
AbbVie and FutureGen Announce Strategic Partnership to Develop Next-Generation IBD Therapy

AbbVie  and FutureGen Biopharmaceutical (Beijing) Co., Ltd. announced a license agreement to develop FG-M701, a next generation TL1A antibody for th...

June 14, 2024 | Friday | News
Bio-Thera's Biosimilar Bevacizumab Avzivi® Receives Positive CHMP Opinion, Moves Closer to European Approval

Bio-Thera Solutions , a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars,  announced th...

June 05, 2024 | Wednesday | News
InnoCare Pharma Completes Patient Enrollment for Phase II Trial of ICP-488, Advancing Novel Psoriasis Treatment

InnoCare Pharma,  a leading biopharmaceutical company dedicated to revolutionizing the treatment of cancer and autoimmune diseases, proudly announces ...

May 16, 2024 | Thursday | News
HUTCHMED Initiates Registrational Phase III Clinical Trial of HMPL-306 for Relapsed / Refractory Acute Myeloid Leukemia in China

  AML, a challenging hematological malignancy, often involves mutations of IDH1 and IDH2 enzymes, necessitating innovative treatment strategies. HMPL...

May 14, 2024 | Tuesday | News
Photocure's Partner Asieris Pharmaceuticals Advances Cevira® for Potential Approval in China

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National...

May 13, 2024 | Monday | News
ArcScan's Insight® 100 Granted NMPA Approval in China, Offering Advanced Solution for Myopia Treatment

ArcScan, Inc., a global medical technology company dedicated to helping ophthalmologists improve vision with ultra-high frequency ultrasound diagnostic ima...

May 13, 2024 | Monday | News
Zai Lab's AUGTYRO™ Approved by NMPA in China for ROS1-Positive NSCLC Treatment

Zai Lab Limited announced that the National Medical Products Administration (NMPA) in China has approved the New Drug Application (NDA) for AUGTYRO™ ...

May 13, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in